August 6, 2019 | STAT

Amid Rising Concern, Pay-to-Play Clinical Trials Are Drawing Federal Scrutiny

Holly Fernandez Lynch, JD, MBE, pointed to research around medical uses of illicit drugs, like medical marijuana and psychedelics, that might have a hard time getting funded through traditional channels, though she acknowledged that that field has increasingly been finding mainstream funding.  But Dr. Steven Joffe, MD, MPH, a pediatric oncologist and bioethicist at the University of Pennsylvania, worries about making exceptions for even a few trials.

Loading tweets...